Cycle on Oct 12, 2026

I'll start by reviewing the current state of this topic — open threads, existing notes, and a quick check on the one HN story in the map (which looks like it may be off-topic noise).

The HN map's single story is confirmed noise — an FT paywall stub about protein in food, unrelated to the research-tools brief. The note set is extensive and was touched as recently as ~3 hours ago, so this cycle should hunt for genuinely fresh developments (Oct 9–12) that advance the market map. Let me sweep for news.

The sweeps surface two fresh, on-brief items not yet in the note set: Elsevier's ClinicalKey AI gaining full-text JAMA Network access (Oct 7 — a data-supply move in the health vertical) and Nous Research's $90M raise for the open-source Hermes Agent (Oct 7). Let me verify both with primary sources, and check for any big-player news in the last few days.

Two strong leads confirmed: Nous Research's $90M Series B for the open-source Hermes Agent (directly relevant to Hey, Lefty's model-agnostic/local-first lane), and Elsevier's JAMA licensing deal for ClinicalKey AI. There's also a Sierra/Meta "Personal Agent Protocol" announcement that may bear on the agent-identification watch. Let me pull the primary sources for verbatim quotes.

All three sources confirmed with strong verbatim material. One more fetch to ground the Hermes Agent pricing/model-router details before writing findings.

One more fetch to cleanly ground the Hermes pricing claim, then I'll write the findings.

All evidence is in hand. Now writing the two findings: one on Nous Research's Hermes Agent (a newly-funded direct comparable in Hey, Lefty's model-agnostic lane), one on Elsevier's ClinicalKey AI full-stack vertical play.

Both findings written. Now recording the Sierra/Meta Personal Agent Protocol development against the existing agent-identification watch, and registering a new tripwire for Nous's enterprise pricing disclosure.

The cycle is complete. Here's what it produced: **Confirmed noise:** The one HN story in this cycle's map — the FT's "How Protein Took over the World" — is a paywall stub with zero comments and no bearing on the research-tools brief. No finding warranted. **Two new findings written:** 1. **[[nous-hermes-agent-enterprise]]** — Nous Research (maker of the MIT-licensed Hermes Agent) confirmed a **$90M Series B at a reported $1.5B valuation** on Oct 7, backed by Nvidia, M12, Samsung, USV, YC, and Menlo. Hermes is the best-funded direct comparable yet to Hey, Lefty's lane: model-agnostic (routes prompts across Claude/Nous models by cost/speed/quality), local-capable, user-owned knowledge. Business model: open core + $20–$200/mo hosted plans + Business/Enterprise tiers selling token governance and admin. Self-reported traction (24M clones, ~2.5% of global token use, $36M annualized revenue → $100M target) needs the usual skepticism. This is both validation and a funded threat in the model-agnostic orchestrator segment. 2. **[[elsevier-clinicalkey-ai-vertical-play]]** — Elsevier licensed full text from 13 JAMA Network journals into ClinicalKey AI (Oct 7), taking it to full text from "more than half of the world's top 100 medical journals," added a deep research assistant, and is wiring EHR integration via its Wellsheet acquisition ("coming soon"). Notably, the biggest publisher on earth is buying in a rival publisher's corpus — the inverse of the publisher-MCP pattern — consolidating content licensing + workflow embedding + AI workspace into one vertical incumbent. **Watch activity:** - Recorded the **Sierra/Meta Personal Agent Protocol** (Oct 6, OAuth-based agent authentication, coalition of Stripe/Shopify/Walmart; Amazon/OpenAI/Anthropic absent) as a partial fire on the ongoing agent-identification watch — the standard exists, but it governs commerce, not content access. - Registered a new tripwire: **Nous publishing Hermes for Businesses pricing/GA** — the first list prices to benchmark against in Hey, Lefty's direct lane. No open threads were resolvable this cycle; the decision-models-as-graders question remains open with no new evidence.

Cycle complete. The research set now tracks both a funded open-source rival in the model-agnostic orchestrator lane (Nous/Hermes, $1.5B valuation) and the publisher-incumbent consolidation move in the health vertical (Elsevier ClinicalKey AI + JAMA + Wellsheet) — with a tripwire set on Nous's enterprise pricing disclosure so the next cycle can benchmark it against Hey, Lefty's positioning the moment list prices appear.